More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients

Kaname Miyashita,Seijiro Shioi,Tatsuhiro Kajitani,Yumiko Koi,Mototsugu Shimokawa,Akitaka Makiyama,Shinya Oda,Taito Esaki
DOI: https://doi.org/10.1038/s41598-024-77770-3
IF: 4.6
2024-11-09
Scientific Reports
Abstract:Microsatellite instability (MSI) is now widely used as an indispensable biomarker. However, the relationship between MSI-H (high) and defective DNA mismatch repair (MMR) is not as straightforward as has been expected. Genome-edited cells carrying Lynch syndrome mutations do not exhibit drastic MSI typical in MSI-H ( i.e. Type B) but more subtle MSI ( i.e. Type A). In this study, we explored a connection between Type A MSI and 5-fluorouracil (5-FU) resistance in colorectal cancer patients. Using our precision and high-resolution MSI assay technique, tumour microsatellites were analysed in 30 colorectal cancer patients treated with FOLFOX or CAPOX. Among 30 tumours, eleven (37%) were judged as Type A MSI-positive. In Type A MSI + tumours, the patient response to fluoropyrimidine and oxaliplatin was significantly poor (Fisher's exact test, p = 0.021). Accordingly, median PFS and OS were significantly poor in Type A + patients (log-rank test, p < 0.001/ p = 0.009). Type A MSI was an independent predictor of patient prognosis in this pilot cohort (Cox regression analysis, p = 0.003). Thus, more subtle Type A MSI better predicts fluoropyrimidine insensitivity in colorectal cancer patients, which may shed light on a hitherto overlooked connection between the MSI phenotypes and drug resistance in human cancer.
multidisciplinary sciences
What problem does this paper attempt to address?